# Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma

*PRI Rank #2 · Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026/rank-2*

| Field | Value |
| --- | --- |
| Rank | #2 |
| 18m citations | 314 |
| Journal | New England Journal of Medicine |
| Year | 2024 |
| DOI | 10.1056/nejmoa2402604 |
| Corresponding authors | Christian U Blank |
| Institution | Netherlands Cancer Institute, France |

**Ranking page:** [Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026](https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026)

**Paper link:** [10.1056/nejmoa2402604](https://doi.org/10.1056/nejmoa2402604)

## Topics

neoadjuvant immunotherapy · nivolumab · ipilimumab · resectable stage III melanoma · macroscopic stage III melanoma · event-free survival · adjuvant immunotherapy · major pathological response · pathological complete response · partial response · Non-response · recurrence-free survival · residual viable tumor · restricted mean survival time · response-driven adjuvant therapy · immune checkpoint inhibitors · surgical resection timing · treatment-related adverse events

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Immunotherapy and Immune Responses Papers, Class of 2026. https://pri.pepkio.com/top-papers/immunotherapy-and-immune-responses/2026. Accessed 2026-07-21.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```